Evaluating Moderately Hypofractionated Radiotherapy with Focal Micro-Boost for Intermediate- to High-Risk Localized Prostate Cancer in an Observational Study
Led by Regina Elena Cancer Institute · Updated on 2026-08-28
82
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a radiotherapy strategy called moderately hypofractionated micro-boost radiotherapy for men with localized intermediate- or high-risk prostate cancer. This approach aims to deliver a higher radiation dose specifically to dominant tumor areas identified by advanced MRI scans, while limiting exposure to surrounding healthy organs. The study is observational and involves patients treated at a single center, focusing on the safety and effectiveness of this targeted treatment.
Participants receive standard care radiotherapy consisting of 20 treatment sessions delivered five times per week. The prostate gland receives a total dose of 62 Gy, with dominant tumor lesions receiving a focal micro-boost up to 71.3 Gy. Seminal vesicles may also be treated with 56 Gy depending on clinical risk. Treatment planning uses CT and multiparametric MRI to precisely target tumors and protect organs at risk. Radiotherapy may be delivered using advanced techniques such as VMAT or CyberKnife.
During the study, data on clinical outcomes, radiological findings, treatment plans, and side effects are collected prospectively. Patients undergo routine follow-up to monitor biochemical recurrence, toxicity, survival, and metastasis over at least three years. The main measure is the rate of biochemical recurrence-free survival at three years, defined by specific PSA criteria or need for additional therapy. The study plans to enroll 82 patients over three years with a total duration of six years for observation and data analysis.
CONDITIONS
Brief Title
Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy
Research Team
G
Giuseppe Sanguineti, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Intermediate or high-risk prostate cancer according to NCCN criteria
No regional or distant metastases
ECOG performance status 0-1
Eligible for moderately hypofractionated radiotherapy in 20 fractions
Presence of at least one PI-RADS 4 or 5 lesion on multiparametric MRI, or a PI-RADS 3 lesion confirmed positive by pathology
Ability to understand Italian and follow study procedures
Provided written informed consent
You will not qualify if you...
Previous local prostate treatments such as radiotherapy, brachytherapy, cryosurgery, high-intensity focused ultrasound, or cryotherapy
Previous pelvic radiotherapy
Presence of nodal or distant metastases confirmed by MRI or PET/CT
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 weeks
Participants receive standard moderately hypofractionated radiotherapy in 20 sessions over four weeks, with a focal micro-boost to dominant tumor lesions based on MRI findings. Treatment planning includes CT and multiparametric MRI scans to target tumors while protecting nearby organs.
Five sessions per week for 4 weeks
Follow-up
Duration - 36 months
Participants undergo routine clinical follow-up to monitor treatment effects, side effects, and cancer control, including PSA testing and toxicity assessments over at least three years.
Regular follow-up visits as per institutional practice
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Evaluating 18F-DCFPyL PETCT Imaging to Assess Treatment Response
in Localized Prostate Cancer Receiving Stereotactic Body Radiation Therapy
Study Comparing High-Intensity Focused Ultrasound and Robot-Assisted Surgery
for Treatment of Localized Prostate Cancer in Men Over 40
Evaluating Moderately Hypofractionated Radiotherapy with Focal Micro-Boost for Intermediate- to High-Risk Localized Prostate Cancer in an Observational Study
Phase II Study of Carbon Ion Radiation Therapy with Targeted Boost for Localized Prostate Cancer Using Advanced Imaging
Study Comparing Safety of Two Types of Post-prostatectomy Radiotherapy for Localized Prostate Cancer
Phase 3 Study Comparing Adaptive and Standard Image-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer
Phase II Study of Neoadjuvant Atezolizumab Alone or Combined with Etrumadenant or Tocilizumab in Men with Localized Prostate Cancer Before Radical Prostatectomy
Study of Oxybutynin Extended-Release Tablets to Help Early Urinary Control After Robotic Prostate Surgery for Localized Prostate Cancer
PRO-BOOST-LC A Phase IIIII Trial Comparing Whole-Gland Prostate Boost Techniques Using HDR or LDR Brachytherapy or SBRT Boost Versus SBRT Monotherapy in Men With Localized or Locally Advanced Prostate Cancer Staged by PSMA PETCT
Study of Safety and Effectiveness of Hypofractionated Radiotherapy
for Treating Localized Prostate Cancer in Men
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
Linda G W Kerkmeijer, Veerle H Groen, Floris J Pos...
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial.